AG337 inhibitor of thymidylate synthase data

AGPH (La Jolla, Calif) announced Phase I findings of efficacy in advanced refractory tumors, with reductions in mass in several patients at the higher doses tested as measured by CT scans and by biochemical indicators.

Side effects were myelosuppression of short duration and mucositis, which was responsive to simple measures, the company said. Further details will be presented at scientific meetings. ...